风湿免疫科指南

订阅

MedSci主页 / 所有栏目 / 风湿免疫科指南

2020 共识声明：Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项

2020-11-06 国外风湿免疫科相关专家小组 Ann Rheum Dis . 2020 Nov 6.

炎症性疾病

Janus激酶(JAK)抑制剂已经被批准用于治疗各种免疫介导的炎症性疾病，本文由29位专家组成专委员会，主要针对Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项提出了4相一半原则和2

中文标题：

2020 共识声明：Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项

英文标题：

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

发布机构：

国外风湿免疫科相关专家小组

发布日期：

2020-11-06

简要介绍：

Janus激酶(JAK)抑制剂已经被批准用于治疗各种免疫介导的炎症性疾病，本文由29位专家组成专委员会，主要针对Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项提出了4相一半原则和26条要点。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2020 共识声明：Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项.pdf)] GetToolGuiderByIdResponse(projectId=1, id=2a0981c002008659, title=2020 共识声明：Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项, enTitle=Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement, guiderFrom=Ann Rheum Dis . 2020 Nov 6., authorId=0, author=, summary=Janus激酶(JAK)抑制剂已经被批准用于治疗各种免疫介导的炎症性疾病，本文由29位专家组成专委员会，主要针对Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项提出了4相一半原则和2, cover=https://img.medsci.cn/20201115/1605370106661_2020535.jpg, journalId=0, articlesId=null, associationId=893, associationName=国外风湿免疫科相关专家小组, associationIntro=null, copyright=0, guiderPublishedTime=Fri Nov 06 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>Janus激酶(JAK)抑制剂已经被批准用于治疗各种免疫介导的炎症性疾病，本文由29位专家组成专委员会，主要针对Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项提出了4相一半原则和26条要点。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=38004, tagName=炎症性疾病)], categoryList=[CategoryDto(categoryId=15, categoryName=风湿免疫科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=38004, guiderKeyword=炎症性疾病, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5741, appHits=280, showAppHits=0, pcHits=880, showPcHits=5461, likes=5, shares=71, comments=19, approvalStatus=1, publishedTime=Sun Nov 15 00:11:14 CST 2020, publishedTimeString=2020-11-06, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Sun Nov 15 00:08:34 CST 2020, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:29:44 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2020 共识声明：Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项.pdf)])
2020 共识声明：Janus激酶(JAK)抑制剂治疗免疫介导性的炎症性疾病的注意事项.pdf
下载请点击：
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1232536, encodeId=b7701232536c5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Thu Jul 14 22:24:37 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056751, encodeId=30f31056e5113, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:08:54 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008187, encodeId=fea8100818e43, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce42642161, createdName=262617146, createdTime=Sun Aug 15 23:14:00 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003645, encodeId=c1941003645d1, content=不错，指导性强！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e91357989, createdName=yrt, createdTime=Thu Jul 29 20:16:31 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996789, encodeId=5fad996e89ef, content=特别棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccaa5434868, createdName=ms5000001426996085, createdTime=Tue Jul 06 12:44:00 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2022-07-14 124d4decm76暂无昵称

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1232536, encodeId=b7701232536c5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Thu Jul 14 22:24:37 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056751, encodeId=30f31056e5113, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:08:54 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008187, encodeId=fea8100818e43, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce42642161, createdName=262617146, createdTime=Sun Aug 15 23:14:00 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003645, encodeId=c1941003645d1, content=不错，指导性强！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e91357989, createdName=yrt, createdTime=Thu Jul 29 20:16:31 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996789, encodeId=5fad996e89ef, content=特别棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccaa5434868, createdName=ms5000001426996085, createdTime=Tue Jul 06 12:44:00 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2021-10-01 13f0c37dm61暂无昵称

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1232536, encodeId=b7701232536c5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Thu Jul 14 22:24:37 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056751, encodeId=30f31056e5113, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:08:54 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008187, encodeId=fea8100818e43, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce42642161, createdName=262617146, createdTime=Sun Aug 15 23:14:00 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003645, encodeId=c1941003645d1, content=不错，指导性强！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e91357989, createdName=yrt, createdTime=Thu Jul 29 20:16:31 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996789, encodeId=5fad996e89ef, content=特别棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccaa5434868, createdName=ms5000001426996085, createdTime=Tue Jul 06 12:44:00 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2021-08-15 262617146

    不错

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1232536, encodeId=b7701232536c5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Thu Jul 14 22:24:37 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056751, encodeId=30f31056e5113, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:08:54 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008187, encodeId=fea8100818e43, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce42642161, createdName=262617146, createdTime=Sun Aug 15 23:14:00 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003645, encodeId=c1941003645d1, content=不错，指导性强！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e91357989, createdName=yrt, createdTime=Thu Jul 29 20:16:31 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996789, encodeId=5fad996e89ef, content=特别棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccaa5434868, createdName=ms5000001426996085, createdTime=Tue Jul 06 12:44:00 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2021-07-29 yrt

    不错，指导性强！

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1232536, encodeId=b7701232536c5, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90f22518616, createdName=124d4decm76暂无昵称, createdTime=Thu Jul 14 22:24:37 CST 2022, time=2022-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056751, encodeId=30f31056e5113, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:08:54 CST 2021, time=2021-10-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1008187, encodeId=fea8100818e43, content=不错, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ce42642161, createdName=262617146, createdTime=Sun Aug 15 23:14:00 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003645, encodeId=c1941003645d1, content=不错，指导性强！, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18e91357989, createdName=yrt, createdTime=Thu Jul 29 20:16:31 CST 2021, time=2021-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=996789, encodeId=5fad996e89ef, content=特别棒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccaa5434868, createdName=ms5000001426996085, createdTime=Tue Jul 06 12:44:00 CST 2021, time=2021-07-06, status=1, ipAttribution=)]
    2021-07-06 ms5000001426996085

    特别棒

    0

以上为热门评论，梅斯医学App还有更多内容